WO2023006656A1 - Oral care comprising solidago extract - Google Patents

Oral care comprising solidago extract Download PDF

Info

Publication number
WO2023006656A1
WO2023006656A1 PCT/EP2022/070778 EP2022070778W WO2023006656A1 WO 2023006656 A1 WO2023006656 A1 WO 2023006656A1 EP 2022070778 W EP2022070778 W EP 2022070778W WO 2023006656 A1 WO2023006656 A1 WO 2023006656A1
Authority
WO
WIPO (PCT)
Prior art keywords
virus
test
oral care
care composition
solidago
Prior art date
Application number
PCT/EP2022/070778
Other languages
French (fr)
Inventor
Amandine Scandolera
Romain Reynaud
Original Assignee
Givaudan Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Givaudan Sa filed Critical Givaudan Sa
Publication of WO2023006656A1 publication Critical patent/WO2023006656A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/005—Antimicrobial preparations

Definitions

  • This disclosure relates to oral care compositions, and more particularly to such compositions containing certain active saponins.
  • Oral care compositions include, not only mouthwashes, toothpastes and tooth powders that are used and then spat out, but also “leave-on” preparations such as dental gums and sprays. They are widely used, and their typical ingredients (including mild abrasives, flavours, detergents, whitening agents, humectants and anticalculus agents) are well known.
  • One way of transmission of the virus is in airborne particles, which are frequently exhaled by people carrying the virus.
  • a way of reducing the exhalation of the virus is to provide a dental care composition containing a material that can kill the virus.
  • Some typical mouthwash components such as ethanol and chlorhexidine gluconate are effective antibacterial agents, but not antiviral.
  • Compounds such as cetylpyridinium chloride (CPC) and povidone-iodine (PI) used in medicinal mouthwashes have been more effective, but have the disadvantage that they are synthetic, and thus of poor biodegradability, and they have the potential to cause irritation to people with allergies.
  • an oral care composition comprising a virucidally-effective proportion and biofilm-inhibiting proportion of a solidago extract.
  • a method of neutralising viruses and biofilms in the oral cavity comprising the application of an oral care composition comprising a virucidally- effective and biofilm-inhibiting proportion of a solidago extract.
  • Solidago extract in the neutralization of viruses and biofilm in the oral cavity.
  • Solidago extract is obtained from the goldenrod plant Solidago virgaurea, a herbaceous perennial plant of the family Asteraceae. Its extract has long been used in folk medicines and is known to be contain flavonoids, triterpene glycosides and triterpenoid saponins. It is commercially available, one example being BucoviaTM, a bioguided fractionation of solid solidago extract.
  • Examples of the saponins found in the extract include those of the following formula: in which Ri and FG are selected according to the following table: in which the abbreviations have the following meanings:
  • the extract is known to have anti-bacterial properties, but it is surprising to find that it is particularly effective against the bacteria that form biofilms and thus dental plaque. In addition, it is especially effective against viruses in the oral cavity, particularly the SARS- CoV-2 virus.
  • the extract may be incorporated into an oral care composition by simply blending it with the other ingredients, all of which are standard ingredients and all of which may be added in art-recognised proportions.
  • the proportion of solidago extract used will be that able to provide a suitable degree of viricidal and biofilm-inhibiting effect. This will depend on the degree of virucvidal effect and biofilm-inhibiting desired, but typical proportions in an oral care composition are from 1-10% by weight, more particularly from 2 - 5%, and more particularly from 2.4-3% by weight of the composition.
  • the oral care composition to which the solidago extract may be added may be any oral care composition, for examples, toothpastes and tooth gels, tooth powders, mouthwashes, dental sprays, dental gels and preparations for treating teeth and gums. These may comprise all the known ingredients of such compositions, used in art- recognised proportions.
  • Example 1 Testing of virucidal properties of solidago extract.
  • bovine coronavirus This commercially-available bovine coronavirus is accepted as an equivalent of the SARS- CoV-2 virus
  • the virus was kept at ⁇ -196°C in liquid nitrogen; before use it was multiplied in the appropriate cellular line as shown in the table below:
  • the cellular line was kept at ⁇ -196°C in liquid nitrogen; before viral inoculum, it appeared as confluent monolayer.
  • the cell debris was removed by centrifugation (400 gn for 15 minutes), and the supernatant containing the virus was used for the test (test virus suspension).
  • Culture Medium and reagent 400 gn for 15 minutes
  • Bovine albumin solution BSA plus sheep erythrocytes with a final concentration 10 times higher than the final concentration of 0.3% (simulating dirty conditions for the medical area): bovine albumin 6 g water for injection 194 ml sterilized through a 0.45 mhi. filter
  • 16 ml of defibrinated sheep blood have been centrifuged at 800 g N for 10 min; the supernatant was discarded and the erythrocytes were re-suspended in PBS. The procedure has been repeated until the supernatant was clarified.
  • Bovine albumin solution BSA plus sheep erythrocytes with a final concentration 50 times higher than the final concentration of 0.3% (simulating dirty conditions for the medical area): bovine albumin 3.8 g water for injection 21.2 ml sterilized through a 0.45 mhi. filter
  • the test was performed at 20°C ⁇ 1 °C.
  • the product test solutions, the interfering substance, and the water were previously stabilised at the test temperature. Assuming a likely level of cytotoxicity of the test item, two cytotoxicity tests were conducted in order to permit the evaluation of a logarithmic reduction according to the requirements of acceptability criteria of the test: one with the unfiltered test item and one with the test item filtered with the S400 HR columns MicroSpinTM.
  • cytotoxicity test was carried out by mixing 8 ml of the product test solution with 1 ml of water for injection and 1 ml of interfering substance two times so one test mixture was treated with filtration technique and the other one not.
  • a cytotoxicity test was carried out by mixing 9.7 ml of the product test solution with 0.1 ml of water for injection and 0.2 ml of interfering substance two times so one test mixture was treated with filtration technique and the other one not.
  • LVP Large-Volume-Plating
  • the assay for checking the cytotoxicity of the test item has been repeated in parallel with the complete test according to the procedure above described for the preliminary check.
  • test solutions Prior the testing, the product test solutions, the interfering substance, and the water were previously stabilised at the test temperature.
  • the test suspension was kept in the ice bath to avoid titre loss.
  • a virus titration was performed for the virus suspension as such, then serial dilutions 1:10 were prepared, starting from virus stock solution of viral suspension, with culture Medium. 0.1 ml were put six-fold on a 96-wells microplate containing the cellular confluent monolayer (>90%) without culture Medium. The outline of the microplate did not receive the viral inoculum and were used as control of cellular line.
  • test item was used neat and diluted with water for injection to concentrations requested in the assay.
  • Test item dilutions were prepared at a concentration 1.25 times higher than the concentration required to perform the test.
  • test item modifies the cellular sensitivity to viral infection.
  • these procedure was followed: 0.1 ml of each dilution, prepared for the cytotoxicity check, for each test concentration was put on 96 wells microplates containing the cellular confluent monolayer; the other microplate in parallel were treated with 0.1 ml of PBS. After 1 hour of incubation at 37°C ⁇ 1°C, the test item and PBS were removed and 0.1 ml of each dilution of the viral test suspension were added six-fold. In parallel at least 6 wells in the microplate did not receive the viral inoculum, but only ice-cold maintenance Medium and used as control of cellular line.
  • 0.3 ml was withdrawn and pipetted into 2.4 ml of ice cold Maintenance Medium. Then 0.3 ml of virus test suspension was added to the previous mixture, and after mixing, the tube was incubated in the ice bath for 30 minutes ⁇ 10 sec.
  • serial decimal dilutions with culture Medium were performed. 0.1 ml of this solution were put on a 96-wells microplate containing the cellular confluent monolayer. The outline of the microplate did not receive the viral inoculum and were used as control of cellular line. After 1 hour of incubation at 37°C ⁇ 1°C 0.1 ml of culture Medium were added to the viral inoculum.
  • CPE cytopathic effect
  • TCID50 infecting activity
  • the appropriate volume of the mixture was diluted in ice-cold culture medium to the lowest apparently non-cytotoxic dilution determined in the preliminary check. 0.1 ml of this solution were put on a defined number of 96-wells microplates containing the cellular confluent monolayer.
  • the outline of the microplate did not receive the viral inoculum and were used as control of cellular line. After 1 hour of incubation at 37°C ⁇ 1°C 0.1 ml of culture Medium were added to the viral inoculum.
  • CPE cytopathic effect
  • the oral care was a mouth spray composition and all proportions are percentages by weight.
  • Component A Water to 100%
  • Component B Water 4 Xylitol 4 BucoviaTM 3
  • the Component A ingredients were mixed at 80°C for 20 minutes at 1000 rpm
  • the xylitol of Component B was solubilised in the water of Component B. It was then added to the Component A, and the other components were then added one by one at room temperature.
  • the peppermint oil of Component C was solubilized in the castor oil at 35-40°C and added to a blend of the glycerol and propylene glycol. This was then added to the mixture of Components A and B under high shear. Finally, Component D was added.
  • the final product was a gelled lotion with a peppermint taste and a pH of 6.3 + 0.2.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Biochemistry (AREA)
  • Nutrition Science (AREA)
  • Inorganic Chemistry (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

An oral care composition comprising a virucidally-effective proportion and biofilm- inhibiting proportion of a solidago extract. The use of solidago brings about a 4 log reduction in viruses. It is particularly effective against coronaviruses, including the SARS-CoV-2 virus.

Description

ORAL CARE COMPRISING SOLIDAGO EXTRACT
This disclosure relates to oral care compositions, and more particularly to such compositions containing certain active saponins.
Oral care compositions include, not only mouthwashes, toothpastes and tooth powders that are used and then spat out, but also “leave-on” preparations such as dental gums and sprays. They are widely used, and their typical ingredients (including mild abrasives, flavours, detergents, whitening agents, humectants and anticalculus agents) are well known.
In recent times, there has been considerable concern about the more frequent emergence of zoonotic viruses, against which humans have no natural resistance. The most recent of these, SARS-CoV-2, has reached a pandemic level, which resulted in widespread disruption of normal activities. The so-called delta-variant is of particular concern, because of its extreme contagiousness. There is therefore an interest in preventing the spread of this virus.
One way of transmission of the virus is in airborne particles, which are frequently exhaled by people carrying the virus. A way of reducing the exhalation of the virus is to provide a dental care composition containing a material that can kill the virus. Some typical mouthwash components such as ethanol and chlorhexidine gluconate are effective antibacterial agents, but not antiviral. Compounds such as cetylpyridinium chloride (CPC) and povidone-iodine (PI) used in medicinal mouthwashes have been more effective, but have the disadvantage that they are synthetic, and thus of poor biodegradability, and they have the potential to cause irritation to people with allergies.
It has now been found that certain natural materials used in dental care compositions are not only effective against viruses such as SARS-CoV-2, but also do not cause irritation. There is therefore provided an oral care composition comprising a virucidally-effective proportion and biofilm-inhibiting proportion of a solidago extract.
There is additionally provided a method of neutralising viruses and biofilms in the oral cavity, comprising the application of an oral care composition comprising a virucidally- effective and biofilm-inhibiting proportion of a solidago extract.
There is further provided the use of a solidago extract in the neutralization of viruses and biofilm in the oral cavity. Solidago extract is obtained from the goldenrod plant Solidago virgaurea, a herbaceous perennial plant of the family Asteraceae. Its extract has long been used in folk medicines and is known to be contain flavonoids, triterpene glycosides and triterpenoid saponins. It is commercially available, one example being Bucovia™, a bioguided fractionation of solid solidago extract. Examples of the saponins found in the extract include those of the following formula:
Figure imgf000003_0001
in which Ri and FG are selected according to the following table:
Figure imgf000003_0002
in which the abbreviations have the following meanings:
Figure imgf000003_0003
The extract is known to have anti-bacterial properties, but it is surprising to find that it is particularly effective against the bacteria that form biofilms and thus dental plaque. In addition, it is especially effective against viruses in the oral cavity, particularly the SARS- CoV-2 virus.
It has been found that exposure to an oral care composition as hereinabove described produces a 4 log reduction in virus content, particularly coronavirus content, after 2 minutes’ exposure. The extract may be incorporated into an oral care composition by simply blending it with the other ingredients, all of which are standard ingredients and all of which may be added in art-recognised proportions. The proportion of solidago extract used will be that able to provide a suitable degree of viricidal and biofilm-inhibiting effect. This will depend on the degree of virucvidal effect and biofilm-inhibiting desired, but typical proportions in an oral care composition are from 1-10% by weight, more particularly from 2 - 5%, and more particularly from 2.4-3% by weight of the composition.
The oral care composition to which the solidago extract may be added may be any oral care composition, for examples, toothpastes and tooth gels, tooth powders, mouthwashes, dental sprays, dental gels and preparations for treating teeth and gums. These may comprise all the known ingredients of such compositions, used in art- recognised proportions.
It is a particular advantage that the use of solidago extract in leave-on formulations does not result in mucosa irritation, something that could reasonably have been expected.
Laboratory testing has demonstrated a 4 log reduction in coronavirus after 2 minutes’ contact, compared with oral care compositions lacking the solidago extract. The disclosure is now further described with reference to the following examples, which are purely exemplary, and which are not intended to be in any way restricting on the scope of the disclosure.
Example 1 Testing of virucidal properties of solidago extract.
The solidago extract (Bucovia™ ex Givaudan), was tested as a 3% aqueous solution. TEST METHOD
1 ASSAY SYSTEM Virus
Bovine Coronavirus (BCoV) RVB-0020
This commercially-available bovine coronavirus is accepted as an equivalent of the SARS- CoV-2 virus The virus was kept at <-196°C in liquid nitrogen; before use it was multiplied in the appropriate cellular line as shown in the table below:
Figure imgf000005_0001
2. CELLS, MEDIA AND REAGENTS
Cellular culture
PT (calf kidney cells) CCLV-RIE 11
The cellular line was kept at <-196°C in liquid nitrogen; before viral inoculum, it appeared as confluent monolayer.
The cell debris was removed by centrifugation (400 gn for 15 minutes), and the supernatant containing the virus was used for the test (test virus suspension). Culture Medium and reagent
EMEM Eagle’s Minimal Essential Medium
DMEM Dulbecco’s Modified Eagle Medium
FBS Foetal Bovine Serum
Pen-Strep (1%) Antibiotics PBS Phosphate Buffer Saline
Trypsine-Edta
BSA Bovine Serum Albumin
Sheep Blood Trypan Blue Water for injection
Growth Medium for cell multiplication: DMEM supplemented with 10% FBS.
Maintenance Medium for virus propagation: EMEM supplemented with 2% FBS.
Interfering substances (dirty conditions for the standard method)
Bovine albumin solution (BSA) plus sheep erythrocytes with a final concentration 10 times higher than the final concentration of 0.3% (simulating dirty conditions for the medical area): bovine albumin 6 g water for injection 194 ml sterilized through a 0.45 mhi. filter
16 ml of defibrinated sheep blood have been centrifuged at 800 gN for 10 min; the supernatant was discarded and the erythrocytes were re-suspended in PBS. The procedure has been repeated until the supernatant was clarified.
6 ml of erythrocytes has been re-suspended in 194 ml of bovine albumin solution prepared as described above. Interfering substances (dirty conditions for the modified method)
Bovine albumin solution (BSA) plus sheep erythrocytes with a final concentration 50 times higher than the final concentration of 0.3% (simulating dirty conditions for the medical area): bovine albumin 3.8 g water for injection 21.2 ml sterilized through a 0.45 mhi. filter
10 ml of defibrinated sheep blood have been centrifuged at 800 gn for 10 min; the supernatant was discarded and the erythrocytes were re-suspended in PBS. The procedure has been repeated until the supernatant was clarified. 3.8 ml of erythrocytes has been re-suspended in 21.2 ml of bovine albumin solution prepared as described above.
3. EXPERIMENTAL DESIGN Test temperature
The test was performed at 20°C± 1 °C.
Experimental conditions The test was performed at the following conditions:
- final concentrations: 97% (maximum testable concentration in the modified method) - 50%
- 5% in test
- contact time: 2 minutes
Interfering substance
This test was conducted using as interfering substance a solution of bovine albumin plus sheep erythrocytes with a final concentration of 0.3% (simulating dirty conditions for the medical area).
4 EXECUTION OF THE ASSAY
Preliminary evaluation of the test product cytotoxicity level
Prior to testing, the product test solutions, the interfering substance, and the water were previously stabilised at the test temperature. Assuming a likely level of cytotoxicity of the test item, two cytotoxicity tests were conducted in order to permit the evaluation of a logarithmic reduction according to the requirements of acceptability criteria of the test: one with the unfiltered test item and one with the test item filtered with the S400 HR columns MicroSpin™.
For each test concentration, a cytotoxicity test was carried out by mixing 8 ml of the product test solution with 1 ml of water for injection and 1 ml of interfering substance two times so one test mixture was treated with filtration technique and the other one not.
For the modified method, a cytotoxicity test was carried out by mixing 9.7 ml of the product test solution with 0.1 ml of water for injection and 0.2 ml of interfering substance two times so one test mixture was treated with filtration technique and the other one not.
Then serial decimal dilutions were performed with Maintenance Medium. 0.1 ml of each dilution of the test item was put on in 96 wells microplates in six replicates. In parallel, at least 6 wells in the microplate did not receive the viral inoculum, but only ice-cold maintenance Medium and they were used as control of cellular line. After 1 hour of incubation at 37°C ± 1°C, 0.1ml of Maintenance Medium was added to each well. The cellular cultures were observed with inverted microscope to detect any cytopathic effect (CPE) due to test item. On the basis of the preliminary results, the filtration procedure with S400 HR columns MicroSpinTM was not applied for the complete test.
For highly cytotoxic test product concentration, the Large-Volume-Plating (LVP) method has been applied. Using the LVP, the lowest apparently non-cytotoxic dilution of the test mixture was added to ice-cold medium after the required contact time and this mixture was added to a defined number of wells containing the cell line in 0.1 ml of maintenance medium.
The assay for checking the cytotoxicity of the test item has been repeated in parallel with the complete test according to the procedure above described for the preliminary check.
Prior the testing, the product test solutions, the interfering substance, and the water were previously stabilised at the test temperature. The test suspension was kept in the ice bath to avoid titre loss.
Assay of viral activity (virus titration)
A virus titration was performed for the virus suspension as such, then serial dilutions 1:10 were prepared, starting from virus stock solution of viral suspension, with culture Medium. 0.1 ml were put six-fold on a 96-wells microplate containing the cellular confluent monolayer (>90%) without culture Medium. The outline of the microplate did not receive the viral inoculum and were used as control of cellular line.
After 1 hour of incubation at 37°C ±1 °C, 0.1 ml of culture Medium were added to viral inoculum.
After the appropriate incubation period, the cellular culture was observed with inverted microscope to detect any cytopathic effect (CPE) due to viral suspension. After this detection the infecting activity (TC I D50 evaluation) was calculated by means of Spearman- Karber method.
Preparation of the test item
The test item was used neat and diluted with water for injection to concentrations requested in the assay. Test item dilutions were prepared at a concentration 1.25 times higher than the concentration required to perform the test.
Check of cellular sensitivity to virus
To verify if the test item modifies the cellular sensitivity to viral infection, these procedure was followed: 0.1 ml of each dilution, prepared for the cytotoxicity check, for each test concentration was put on 96 wells microplates containing the cellular confluent monolayer; the other microplate in parallel were treated with 0.1 ml of PBS. After 1 hour of incubation at 37°C ± 1°C, the test item and PBS were removed and 0.1 ml of each dilution of the viral test suspension were added six-fold. In parallel at least 6 wells in the microplate did not receive the viral inoculum, but only ice-cold maintenance Medium and used as control of cellular line.
After 1 hour of incubation at 37°C ±1°C 0.1 ml of culture Medium were added to the viral inoculum. After 5 days, the cellular culture was observed with inverted microscope to detect any cytopathic effect (CPE) due to viral suspension. After this detection the infecting activity (TCID50) was calculated by means of Spearman-Karber method both in the cellular culture treated with the test item and in that treated with PBS.
Check of suppression of disinfectant activity
For each test concentration, 1 part of interfering substance was added to 1 part of Maintenance Medium and to 8 parts of the product test solution at the required test concentrations.
For the modified method, 0.2 parts of interfering substance were added to 0.1 part of Maintenance Medium and to 9.7 parts of the product test solution (97%).
At time zero, 0.3 ml was withdrawn and pipetted into 2.4 ml of ice cold Maintenance Medium. Then 0.3 ml of virus test suspension was added to the previous mixture, and after mixing, the tube was incubated in the ice bath for 30 minutes ± 10 sec.
After this period, serial dilutions 1:10 with ice cold Maintenance Medium were performed. 0.1 ml of the each dilutions was transferred onto 96 wells microplates six-fold and incubated at 37°C ±1°C for 1 hour. Then, 0.1 ml of Maintenance Medium was added. In parallel at least 6 wells in the microplate did not receive the viral inoculum, but only ice-cold maintenance Medium and used as control of cellular line. After the appropriate incubation period, the cellular cultures were observed with inverted microscope to detect any cytopathic effect (CPE) due to viral suspension. After this detection, the infecting activity (TCID50) was calculated by means of Spearman-Karber method.
Check of viral inactivation (Test) and virus control vitality (for all test product concentrations)
For each concentration, 1 ml of interfering substance was mixed with 1 ml of virus test suspension, then vortexed. 8 ml of the product test solution was added to this solution and left in contact for the required contact times at the required test temperature. For the modified method, 0.2 ml of interfering substance was mixed with 0.1 ml of virus test suspension, then vortexed. 9.7 ml of the product test solution (97%) was added to this solution and left in contact for the required contact time at the required test temperature.
After the contact time, serial decimal dilutions with culture Medium were performed. 0.1 ml of this solution were put on a 96-wells microplate containing the cellular confluent monolayer. The outline of the microplate did not receive the viral inoculum and were used as control of cellular line. After 1 hour of incubation at 37°C ±1°C 0.1 ml of culture Medium were added to the viral inoculum.
After the appropriate incubation period, the cellular culture was observed with inverted microscope to detect any cytopathic effect (CPE) due to viral suspension.
In a second time the same test described above, was performed with water for injection instead of the test item, after 0 and maximum contact time tested (virus control).
After this detection the infecting activity (TCID50) was calculated by means of Spearman- Karber method both in the cellular culture treated with the test item and in the virus control.
Determination of the residual virus titre by the Large Volume Plating (LVP) method (only for 97%)
0.2 ml of interfering substance was mixed with 0.1 ml of virus test suspension, then vortexed. 9.7 ml of the product test solution (97%) was added to this solution and left in contact for the required contact time at the required test temperature.
After the contact time, the appropriate volume of the mixture was diluted in ice-cold culture medium to the lowest apparently non-cytotoxic dilution determined in the preliminary check. 0.1 ml of this solution were put on a defined number of 96-wells microplates containing the cellular confluent monolayer.
The outline of the microplate did not receive the viral inoculum and were used as control of cellular line. After 1 hour of incubation at 37°C ±1°C 0.1 ml of culture Medium were added to the viral inoculum.
After the appropriate incubation period, the cellular culture was observed with inverted microscope to detect any cytopathic effect (CPE) due to viral suspension.
The test procedure showed that there was a 4 log reduction in virus after 2 minutes of contact. Example 2
Preparation of an oral care composition. The oral care was a mouth spray composition and all proportions are percentages by weight.
Component A Water to 100%
Sodium benzoate 0.5 Xanthan gum 0.35
Component B Water 4 Xylitol 4 Bucovia™ 3
Sodium hyaluronate 0.1 Component C
PEG-40 hydrogenated castor oil 2
Menthe piperita oil 0.08
Glycerol 6
Propylene glycol 5
Component D
Water 3
Trisodium citrate 0.276
Citric acid 0.024
The Component A ingredients were mixed at 80°C for 20 minutes at 1000 rpm
The xylitol of Component B was solubilised in the water of Component B. It was then added to the Component A, and the other components were then added one by one at room temperature.
The peppermint oil of Component C was solubilized in the castor oil at 35-40°C and added to a blend of the glycerol and propylene glycol. This was then added to the mixture of Components A and B under high shear. Finally, Component D was added.
The final product was a gelled lotion with a peppermint taste and a pH of 6.3 + 0.2.

Claims

Claims:
1. An oral care composition comprising a virucidal ly-effective proportion and biofilm- inhibiting proportion of a solidago extract.
2. An oral care composition according to claim 1 , in which the virus comprises coronavirus.
3. An oral care composition according to claim 2, in which the coronavirus comprises the SARS-CoV-2 virus.
4. A oral care composition according to claim 1 , in which the virucidal effectiveness is such that there is a 4 log reduction in virus content after 2 minutes’ exposure.
5. An oral care composition according to claim 1 , in which the solidago extract is present in the composition in the proportion of from 1-10%, more particularly from 2 - 5%, and even more particularly from 2.4-3% by weight of the composition
6. A method of neutralising viruses and biofilms in the oral cavity, comprising the application of an oral care composition comprising a virucidally-effective and biofilm- inhibiting proportion of a solidago extract.
7. A method according to claim 6, in which the virus is a coronavirus, particularly the SARS-CoV-2 virus.
8. Use of a solidago extract in the preparation of an oral care composition for the neutralization of viruses and biofilm in the oral cavity.
9. Use according to claim 8 in which the virus is a coronavirus, particularly the SARS- CoV-2 virus.
PCT/EP2022/070778 2021-07-29 2022-07-25 Oral care comprising solidago extract WO2023006656A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB2110903.8 2021-07-29
GBGB2110903.8A GB202110903D0 (en) 2021-07-29 2021-07-29 Oral care

Publications (1)

Publication Number Publication Date
WO2023006656A1 true WO2023006656A1 (en) 2023-02-02

Family

ID=77651434

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2022/070778 WO2023006656A1 (en) 2021-07-29 2022-07-25 Oral care comprising solidago extract

Country Status (2)

Country Link
GB (1) GB202110903D0 (en)
WO (1) WO2023006656A1 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005002610A1 (en) * 2003-07-01 2005-01-13 Shirong Lou Traditional chinese medicine for treating and preventing sars virus
CN104434758A (en) * 2014-11-20 2015-03-25 惠州市欧野科技有限公司 Health toothpaste
CN113041289A (en) * 2021-04-20 2021-06-29 贵州中医药大学 Compound goldenrod spray dry powder anti-RNA virus drug target activity and application

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005002610A1 (en) * 2003-07-01 2005-01-13 Shirong Lou Traditional chinese medicine for treating and preventing sars virus
CN104434758A (en) * 2014-11-20 2015-03-25 惠州市欧野科技有限公司 Health toothpaste
CN113041289A (en) * 2021-04-20 2021-06-29 贵州中医药大学 Compound goldenrod spray dry powder anti-RNA virus drug target activity and application

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DATABASE GNPD [online] MINTEL; 16 March 2021 (2021-03-16), ANONYMOUS: "Fresh Lemon Flavoured Propolis Breath Freshener Spray", XP055909104, retrieved from https://www.gnpd.com/sinatra/recordpage/8566875/ Database accession no. 8566875 *
DATABASE GNPD [online] MINTEL; 4 February 2021 (2021-02-04), ANONYMOUS: "Dental Foam", XP055909115, retrieved from https://www.gnpd.com/sinatra/recordpage/8456929/ Database accession no. 8456929 *
FURSENCO CORNELIA ET AL: "Solidago virgaurea L.: A Review of Its Ethnomedicinal Uses, Phytochemistry, and Pharmacological Activities", vol. 10, no. 12, 30 November 2020 (2020-11-30), pages 1619, XP055909321, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7761148/pdf/biomolecules-10-01619.pdf> DOI: 10.3390/biom10121619 *
HERRERA DAVID ET AL: "Is the oral cavity relevant in SARS-CoV-2 pandemic?", CLINICAL ORAL INVESTIGATIONS, SPRINGER, BERLIN, DE, vol. 24, no. 8, 23 June 2020 (2020-06-23), pages 2925 - 2930, XP037190535, ISSN: 1432-6981, [retrieved on 20200623], DOI: 10.1007/S00784-020-03413-2 *
NN: "NATUREX TACKLES THE ORAL CARE MARKET WITH A NEW MICROBIOTA-BALANCING NATURAL ACTIVE", 21 February 2018 (2018-02-21), pages 1 - 2, XP055909315, Retrieved from the Internet <URL:https://www.naturex.com/Media2/Press-releases/Naturex-tackles-the-Oral-Care-market-with-a-new-microbiota-balancing-natural-active> [retrieved on 20220405] *
PRÊCHEUR ISABELLE ET AL: "Solidago virgaurea L. Plant Extract Targeted against Candida albicans to Reduce Oral Microbial Biomass: A Double Blind Randomized Trial on Healthy Adults", ANTIBIOTICS (BASEL, SWITZERLAND) 2015, vol. 9, no. 4, 25 March 2020 (2020-03-25), pages 137, XP055909429, ISSN: 2079-6382, DOI: 10.3390/antibiotics9040137 *
TATLI CANKAYA I. IREM ET AL: "Potential and Prophylactic Use of Plants Containing Saponin-Type Compounds as Antibiofilm Agents against Respiratory Tract Infections", EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, vol. 2021, 23 July 2021 (2021-07-23), US, pages 1 - 14, XP055909331, ISSN: 1741-427X, DOI: 10.1155/2021/6814215 *

Also Published As

Publication number Publication date
GB202110903D0 (en) 2021-09-15

Similar Documents

Publication Publication Date Title
CN101687002B (en) Extract of trigonella foenum-graecum
KR0180001B1 (en) Method for inhibiting and treating infection caused by influenza virus
Kharouf et al. Polyphenols in dental applications
JP6774435B2 (en) Nasal congestion clearing composition with antiviral activity
RU2416391C1 (en) Composition for oral cavity care
CN1223546A (en) Antimicrobial treatment for herpes simplex virus and other infectious diseases
CN102626378A (en) Oral care composition containing extract of unoxidized camellia
CN107308186A (en) It is used for the biomedical applications and the bismuth mercaptan of other purposes for the treatment of for including bacterial biof iotalm as antiseptic
JPH02229107A (en) Composition for prevention and medical treatment of periodontosis
KR102338256B1 (en) Hand sanitizer composition that contains ionized calcium and has excellent skin moisturizing effect, sterilization effect and viral effect
CN108938558A (en) A kind of nano-emulsion compound and preparation method and application
WO2023006656A1 (en) Oral care comprising solidago extract
JP2001089383A (en) Composition for oral cavity and ophthalmology
US20230355668A1 (en) Hydroxyapatite composition for treatment and/or prevention of a virus infection
EP3189842A1 (en) Composition for preventing hair loss or promoting hair growth, containing oleanolic acid derivative and pharmaceutically acceptable salt thereof
JP4286195B2 (en) Oral composition
JP5389334B2 (en) Vascular endothelial growth factor production promoter and hair growth hair external preparation
WO2023006662A1 (en) Skin care comprising saponin-containing quillaja extract
TR202022177A1 (en) FORMULATION CONTAINING ESSENTIAL OIL AND PROPOLIS
JP4614423B2 (en) Nasal composition for allergic rhinitis
Vajrabhaya et al. Efficacy of Aloe vera toothpaste during active periodontal treatment: A clinical study
RU2646494C1 (en) Cosmetic composition against inflammation on skin for usage as part of the cosmetic products
JP6853547B2 (en) Composition for inhibiting collagen degradation
Esmaeilzadeh et al. Antimicrobial and cytotoxic properties of calcium-enriched mixture cement, Iranian propolis, and propolis with herbal extracts in primary dental pulp stem cells
CA2083061C (en) Peat-derived bioactive products and pharmaceutical and cosmetic compositions containing them

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22754865

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10202400000306

Country of ref document: CH

NENP Non-entry into the national phase

Ref country code: DE